- Home
- HRMY vs HMN Comparison
HRMY vs HMN Comparison
Compare HRMY & HMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HRMY | HMN |
|---|---|---|
| Founded | 2017 | 1945 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.8B |
| IPO Year | 2020 | 1991 |
Fundamental Metrics
Financial Performance| Metric | HRMY | HMN |
|---|---|---|
| Price | $36.78 | $43.35 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $49.75 | $46.75 |
| AVG Volume (30 Days) | ★ 615.1K | 198.9K |
| Earning Date | 02-24-2026 | 02-03-2026 |
| Dividend Yield | N/A | ★ 3.27% |
| EPS Growth | 50.44 | ★ 56.80 |
| EPS | 3.17 | ★ 3.95 |
| Revenue | $825,944,000.00 | ★ $1,675,600,000.00 |
| Revenue This Year | $23.29 | $7.70 |
| Revenue Next Year | $15.98 | $6.46 |
| P/E Ratio | $11.58 | ★ $10.84 |
| Revenue Growth | ★ 21.13 | 5.44 |
| 52 Week Low | $25.52 | $37.21 |
| 52 Week High | $40.93 | $48.33 |
Technical Indicators
Market Signals| Indicator | HRMY | HMN |
|---|---|---|
| Relative Strength Index (RSI) | 48.42 | 37.74 |
| Support Level | $35.16 | $41.74 |
| Resistance Level | $37.08 | $43.65 |
| Average True Range (ATR) | 1.43 | 1.14 |
| MACD | -0.21 | -0.23 |
| Stochastic Oscillator | 43.22 | 32.81 |
Price Performance
Historical ComparisonAbout HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About HMN Horace Mann Educators Corporation
Horace Mann Educators Corp is a diversified insurance holding company that markets and underwrites personal lines of property and casualty insurance, retirement annuities, and life insurance. The company's property and casualty operations focus on automobile and homeowner insurance, while the retirement annuities are 403(b) tax-qualified products. Horace Mann Educators markets its products to kindergarten through 12th-grade teachers, administrators, and other employees of public schools and their families. The Company conducts and manages its business in four reporting segments: (1) Property & Casualty, (2) Life & Retirement, (3) Supplemental & Group Benefits and (4) Corporate & Other.